8-K: LifeVantage Reports Mixed Q1 Results: Revenue Declines but Profitability Improves

LifeVantage Corporation reported a decrease in revenue for the first quarter of fiscal year 2025, but saw improvements in net income and adjusted EBITDA.

Summary

• LifeVantage Corporation's revenue for the first quarter of fiscal year 2025 was $47.2 million, which is an 8.1% decrease compared to the same period last year.
• Excluding the impact of foreign currency fluctuations, revenue decreased by approximately 7.7%.
• Revenue in the Americas decreased by 4.2%, while revenue in Asia/Pacific & Europe decreased by 19.7%, or 18.7% on a constant currency basis.
• Net income per diluted share increased to $0.14, compared to $0.05 in the prior year.
• Adjusted earnings per diluted share rose to $0.15, up from $0.13 a year ago.
• Adjusted EBITDA increased to $4.4 million, compared to $4.0 million in the same quarter last year.
• The company repurchased 0.1 million shares of its common stock for $1.1 million during the quarter.
• A cash dividend of $0.04 per common share was declared, payable on December 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While profitability metrics improved, the significant revenue decline and decrease in active accounts are concerning. The launch of a new product is a positive, but its impact is yet to be fully realized.

Positives

• Net income per diluted share increased significantly to $0.14 from $0.05 year-over-year.
• Adjusted earnings per diluted share improved to $0.15 from $0.13 year-over-year.
• Adjusted EBITDA increased by 11% to $4.4 million.
• Adjusted EBITDA margin improved by 160 basis points.
• The company launched a new product, the MindBody GLP-1 System, which has seen an overwhelming initial response.
• The company has a strong balance sheet with no debt outstanding.
• The company declared a cash dividend of $0.04 per share.

Negatives

• Revenue decreased by 8.1% year-over-year to $47.2 million.
• Revenue in the Americas decreased by 4.2%.
• Revenue in Asia/Pacific & Europe decreased by 19.7%, or 18.7% on a constant currency basis.
• Cash used in operations was $0.6 million, compared to cash provided of $4.8 million in the same period last year.
• Active Independent Consultants decreased by 9.6% to 47,000.
• Active Customers decreased by 10.6% to 76,000.
• Total Active Accounts decreased by 10.2% to 123,000.

Risks

• The company faces risks related to global economic and operating environments, including potential impacts from COVID-19.
• The company's revenue is declining, particularly in the Asia/Pacific & Europe region.
• The company's active consultant and customer base is shrinking.
• The company's cash flow from operations has turned negative.

Future Outlook

The company continues to expect revenue in the range of $200 million to $210 million, adjusted EBITDA of $18 million to $21 million, and adjusted earnings per share in the range of $0.70 to $0.80 for fiscal year 2025. The company expects a full year tax rate of approximately 25% to 27%.

Management Comments

• Steve Fife, President and CEO, stated that it's an incredible time to be at LifeVantage due to the launch of the MindBody GLP-1 System.
• Management is focused on optimizing cost structure while strategically investing in growth and innovation.
• Management believes the company is well positioned to deliver future growth and significant long-term value for stockholders.

Industry Context

LifeVantage operates in the competitive health and wellness industry, which is seeing increased demand for weight management solutions. The launch of the MindBody GLP-1 System positions them to capitalize on this trend, but they face challenges in maintaining revenue growth and active customer numbers.

Comparison to Industry Standards

• Direct selling companies like Herbalife and Nu Skin have also faced challenges in maintaining revenue growth in recent periods, suggesting a broader trend in the industry.
• LifeVantage's adjusted EBITDA margin improvement of 160 basis points is a positive sign, but needs to be sustained.
• The decline in active consultants and customers is a concern, as these are key drivers of revenue for direct selling companies.
• The company's revenue decline of 8.1% is worse than some competitors in the health and wellness space, but the improvement in profitability is a positive sign.

Stakeholder Impact

• Shareholders will be impacted by the decrease in revenue, but may be encouraged by the increase in profitability and the dividend announcement.
• Employees may be affected by the company's cost optimization efforts.
• Customers may benefit from the new product launch, but the decrease in active customers is a concern.
• Independent consultants may be impacted by the decrease in active consultants and the overall revenue decline.

Next Steps

• The company will continue to focus on optimizing its cost structure.
• The company will continue to be strategic with its investments in growth and innovation.
• The company will monitor the performance of the newly launched MindBody GLP-1 System.
• The company will hold an investor conference call to discuss the results.

Key Dates

Keywords

LifeVantage, Financial Results, Revenue, Net Income, EBITDA, Direct Sales, Nutrigenomics, Health and Wellness, Dividend, Share Repurchase